Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial therapies for serious and life-threatening infections. The company operates within the biopharmaceutical and anti-infective drug development industries, with a primary emphasis on addressing antibiotic-resistant bacterial infections. Its lead development program targets Clostridioides difficile (C. difficile) infections, a major cause of hospital-acquired illness with significant unmet medical need.
The company’s core value proposition centers on its proprietary approach to antibacterial drug design, which aims to selectively inhibit bacterial DNA replication while minimizing disruption to the normal gut microbiome. Acurx Pharmaceuticals was founded in 2017 and became publicly listed on the Nasdaq Capital Market under the ticker ACXP in 2021. Since its inception, the company has remained focused on advancing its lead clinical candidate through human trials while maintaining a streamlined, research-driven operating model.
Business Operations
Acurx Pharmaceuticals’ operations are primarily organized around research and development (R&D) activities rather than commercial production. The company’s principal product candidate, ibezapolstat, is an orally administered antibiotic designed for the treatment of C. difficile infection (CDI). Revenue generation to date has been limited, as the company has not yet commercialized any products and relies primarily on equity financing to fund operations.
Operationally, the company conducts preclinical and clinical development through a combination of internal scientific leadership and outsourced contract research organizations. Acurx does not currently report distinct commercial segments and has no marketed products. Its intellectual property portfolio, including composition-of-matter patents related to ibezapolstat, represents a critical strategic asset supporting its development pipeline.
Strategic Position & Investments
Acurx’s strategic direction is centered on advancing ibezapolstat through later-stage clinical development and positioning it as a differentiated therapy for CDI by emphasizing narrow-spectrum activity and reduced recurrence risk. The company has highlighted the potential for its drug candidate to address limitations of existing broad-spectrum antibiotics, which can contribute to resistance and microbiome disruption.
The company has not disclosed any completed material acquisitions or equity investments in other operating businesses. Instead, its capital allocation strategy has focused on internal R&D spending and clinical trial execution. Acurx has indicated interest in potential future strategic partnerships or licensing arrangements, particularly to support commercialization, though no definitive agreements have been publicly confirmed based on available filings.
Geographic Footprint
Acurx Pharmaceuticals is headquartered in the United States, with its principal executive offices located in New York, New York. Its operational footprint is primarily domestic, reflecting its status as a development-stage biotechnology company without global manufacturing or sales infrastructure.
Clinical development activities involve trial sites within North America, and the company has indicated that future studies may include international locations depending on regulatory strategy and trial design. As of the most recent public disclosures, Acurx does not maintain permanent offices or subsidiaries outside the United States.
Leadership & Governance
Acurx Pharmaceuticals was founded by executives with prior experience in pharmaceutical development and commercialization. The leadership team emphasizes a science-driven, capital-efficient strategy focused on advancing targeted antibacterial therapies through regulatory approval while preserving shareholder value.
Key executives include:
- David P. Luci – Chief Executive Officer
- Robert DeLuccia – Chief Financial Officer
Public disclosures identify a small executive management team, consistent with the company’s development-stage profile. Information regarding additional executive officers or changes in leadership beyond those listed above is inconclusive based on available public sources.